196 related articles for article (PubMed ID: 33004795)
1. Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases.
Yang SW; Huang X; Lin W; Min J; Miller DJ; Mayasundari A; Rodrigues P; Griffith EC; Gee CT; Li L; Li W; Lee RE; Rankovic Z; Chen T; Potts PR
Nat Commun; 2020 Oct; 11(1):4931. PubMed ID: 33004795
[TBL] [Abstract][Full Text] [Related]
2. A Cancer-Specific Ubiquitin Ligase Drives mRNA Alternative Polyadenylation by Ubiquitinating the mRNA 3' End Processing Complex.
Yang SW; Li L; Connelly JP; Porter SN; Kodali K; Gan H; Park JM; Tacer KF; Tillman H; Peng J; Pruett-Miller SM; Li W; Potts PR
Mol Cell; 2020 Mar; 77(6):1206-1221.e7. PubMed ID: 31980388
[TBL] [Abstract][Full Text] [Related]
3. Regulation of MAGE-A3/6 by the CRL4-DCAF12 ubiquitin ligase and nutrient availability.
Ravichandran R; Kodali K; Peng J; Potts PR
EMBO Rep; 2019 Jul; 20(7):e47352. PubMed ID: 31267705
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of the MAGE protein family in stress response pathways.
Florke Gee RR; Chen H; Lee AK; Daly CA; Wilander BA; Fon Tacer K; Potts PR
J Biol Chem; 2020 Nov; 295(47):16121-16155. PubMed ID: 32921631
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.
Lee AK; Potts PR
J Mol Biol; 2017 Apr; 429(8):1114-1142. PubMed ID: 28300603
[TBL] [Abstract][Full Text] [Related]
6. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.
Doyle JM; Gao J; Wang J; Yang M; Potts PR
Mol Cell; 2010 Sep; 39(6):963-74. PubMed ID: 20864041
[TBL] [Abstract][Full Text] [Related]
7. Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation.
Su S; Chen X; Geng J; Minges JT; Grossman G; Wilson EM
Mol Cell Endocrinol; 2017 Jan; 439():1-9. PubMed ID: 27720894
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Structural Basis of the Selectivity of Potent Cyclic Peptide Inhibitors of MAGE-A4.
Fleming MC; Chiou LF; Tumbale PP; Droby GN; Lim J; Norris-Drouin JL; Williams JG; Pearce KH; Williams RS; Vaziri C; Bowers AA
J Med Chem; 2022 May; 65(10):7231-7245. PubMed ID: 35522528
[TBL] [Abstract][Full Text] [Related]
9. MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity.
Xiao TZ; Suh Y; Longley BJ
Arch Biochem Biophys; 2014 Dec; 563():136-44. PubMed ID: 25107531
[TBL] [Abstract][Full Text] [Related]
10. The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex.
Kozakova L; Vondrova L; Stejskal K; Charalabous P; Kolesar P; Lehmann AR; Uldrijan S; Sanderson CM; Zdrahal Z; Palecek JJ
Cell Cycle; 2015; 14(6):920-30. PubMed ID: 25590999
[TBL] [Abstract][Full Text] [Related]
11. Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers.
Minges JT; Su S; Grossman G; Blackwelder AJ; Pop EA; Mohler JL; Wilson EM
J Biol Chem; 2013 Jan; 288(3):1939-52. PubMed ID: 23172223
[TBL] [Abstract][Full Text] [Related]
12. Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.
Su S; Minges JT; Grossman G; Blackwelder AJ; Mohler JL; Wilson EM
J Biol Chem; 2013 Aug; 288(34):24809-24. PubMed ID: 23853093
[TBL] [Abstract][Full Text] [Related]
13. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
Hartmann S; Zwick L; Scheurer MJJ; Fuchs AR; Brands RC; Seher A; Böhm H; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2018 Apr; 22(3):1477-1486. PubMed ID: 29034444
[TBL] [Abstract][Full Text] [Related]
15. The MAGE protein family and cancer.
Weon JL; Potts PR
Curr Opin Cell Biol; 2015 Dec; 37():1-8. PubMed ID: 26342994
[TBL] [Abstract][Full Text] [Related]
16. A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis.
Gao Y; Mutter-Rottmayer E; Greenwalt AM; Goldfarb D; Yan F; Yang Y; Martinez-Chacin RC; Pearce KH; Tateishi S; Major MB; Vaziri C
Nat Commun; 2016 Jul; 7():12105. PubMed ID: 27377895
[TBL] [Abstract][Full Text] [Related]
17. Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase.
Gur I; Fujiwara K; Hasegawa K; Yoshikawa K
PLoS One; 2014; 9(6):e99503. PubMed ID: 24911587
[TBL] [Abstract][Full Text] [Related]
18. Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.
Minges JT; Grossman G; Zhang P; Kafri T; Wilson EM
J Biol Chem; 2015 Oct; 290(41):25174-87. PubMed ID: 26330556
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
20. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
